| Literature DB >> 35013866 |
Sarah A Keim1,2,3, Abigail Jude4, Katie Smith4, Aiman Q Khan4, Daniel L Coury4,5, Joseph Rausch4,5, Shivika Udaipuria4, Megan Norris4,5,6, Lindsay R Bartram4,5, Anita R Narayanan4,5, Lynette K Rogers4,5.
Abstract
This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1β, IL-2, IFNγ, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d = - 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209.Entities:
Keywords: Autism spectrum disorder; IL-2; Inflammation; Omega-3 fatty acids; Omega-6 fatty acids; Young child
Year: 2022 PMID： 35013866 PMCID： PMC9271516 DOI： 10.1007/s10803-021-05396-9
Source DB: PubMed Journal: J Autism Dev Disord ISSN： 0162-3257